Gregory D. Espenan

739 total citations
16 papers, 574 citations indexed

About

Gregory D. Espenan is a scholar working on Oncology, Epidemiology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Gregory D. Espenan has authored 16 papers receiving a total of 574 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 9 papers in Epidemiology and 6 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Gregory D. Espenan's work include Neuroendocrine Tumor Research Advances (9 papers), Lung Cancer Research Studies (6 papers) and Neuroblastoma Research and Treatments (5 papers). Gregory D. Espenan is often cited by papers focused on Neuroendocrine Tumor Research Advances (9 papers), Lung Cancer Research Studies (6 papers) and Neuroblastoma Research and Treatments (5 papers). Gregory D. Espenan collaborates with scholars based in United States and Netherlands. Gregory D. Espenan's co-authors include Eugene A. Woltering, Lowell Anthony, Kevin E. McCarthy, M. Cronin, Thomas M. O’Dorisio, Ebrahim S. Delpassand, M. Sue O’Dorisio, James C. Watson, Douglas A. Balster and Catherine T. Anthony and has published in prestigious journals such as Annals of Surgery, British Journal of Cancer and Journal of the American College of Surgeons.

In The Last Decade

Gregory D. Espenan

16 papers receiving 549 citations

Peers

Countries citing papers authored by Gregory D. Espenan

Since Specialization

Citations

This map shows the geographic impact of Gregory D. Espenan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gregory D. Espenan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gregory D. Espenan more than expected).

Fields of papers citing papers by Gregory D. Espenan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gregory D. Espenan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gregory D. Espenan. The network helps show where Gregory D. Espenan may publish in the future.

Co-authorship network of co-authors of Gregory D. Espenan

This figure shows the co-authorship network connecting the top 25 collaborators of Gregory D. Espenan. A scholar is included among the top collaborators of Gregory D. Espenan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gregory D. Espenan. Gregory D. Espenan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

#	Work	Indexed citations
1	Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE for Patients With Somatostatin Receptor–Expressing Neuroendocrine Tumors 2014 ·Pancreas ·Ebrahim S. Delpassand, Amin Samarghandi, Sara Zamanian, Edward M. Wolin, (unknown), Gregory D. Espenan, Jack L. Erion, Thomas M. O’Dorisio, Larry K. Kvols, (unknown), (unknown), (unknown), Eric P. Krenning, Alireza Mojtahedi	108
2	An Extended Phase II Trial of Iodine-125 Methylene Blue for Sentinel Lymph Node Identification in Women with Breast Cancer 2013 ·Journal of the American College of Surgeons ·(unknown), (unknown), Thomas R. Maloney, Gregory D. Espenan, Yi‐Zarn Wang, (unknown), (unknown), Daniel M. Frey, C Chappuis, Eugene A. Woltering	3
3	Long-Term Survival, Toxicity Profile, and role of F-18 FDG PET/CT scan in Patients with Progressive Neuroendocrine Tumors Following Peptide Receptor Radionuclide Therapy with High Activity In-111 Pentetreotide 2012 ·Theranostics ·Ebrahim S. Delpassand, Amin Samarghandi, (unknown), Sara Zamanian, Gregory D. Espenan, Roozbeh Sharif, Shawn MacKenzie, Kambiz Kosari, Omar Barakat, (unknown), John E. Seng, Lowell Anthony	22
4	Safety and Efficacy of Radionuclide Therapy with High-Activity In-111 Pentetreotide in Patients with Progressive Neuroendocrine Tumors 2008 ·Cancer Biotherapy and Radiopharmaceuticals ·Ebrahim S. Delpassand, Jennifer Sims‐Mourtada, Hitomi Saso, Ali Azhdarinia, Faramarz Ashoori, (unknown), Gregory D. Espenan, Warren H. Moore, Eugene A. Woltering, Lowell Anthony	40
5	A Phase I/II Trial of 125I Methylene Blue for One-Stage Sentinel Lymph Node Biopsy 2007 ·Annals of Surgery ·(unknown), Yi‐Zarn Wang, Gregory D. Espenan, Thomas R. Maloney, (unknown), (unknown), Alan Stolier, (unknown), Bruce Torrance, (unknown), (unknown), Eugene A. Woltering	16
6	Development of ¹²⁵I‐methylene blue for sentinel lymph node biopsy 2006 ·Journal of Surgical Oncology ·(unknown), (unknown), (unknown), Catherine T. Anthony, (unknown), Jessica L. Thomson, Yi‐Zarn Wang, Gregory D. Espenan, Thomas R. Maloney, (unknown), Eugene A. Woltering	9
7	Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies 2002 ·Seminars in Nuclear Medicine ·Lowell Anthony, Eugene A. Woltering, Gregory D. Espenan, M. Cronin, (unknown), Kevin E. McCarthy	202
8	Portable Chest Radiographs in the Intensive Care Units: Referral Patterns and Estimated Cumulative Radiation Exposures 2002 ·Journal of Thoracic Imaging ·(unknown), L Diethelm, Gregory D. Espenan	3
9	Growing vascular endothelial cells express somatostatin subtype 2 receptors 2001 ·British Journal of Cancer ·James C. Watson, Douglas A. Balster, (unknown), Thomas M. O’Dorisio, M. Sue O’Dorisio, Gregory D. Espenan, (unknown), Eugene A. Woltering	76
10	Progressive nuclear translocation of somatostatin analogs. 2000 ·PubMed ·Conrad A. Hornick, Catherine T. Anthony, (unknown), Bryan M. Gebhardt, Gregory D. Espenan, Eugene A. Woltering	46
11	Synthesis and characterization of multiply‐tyrosinated, multiply‐iodinated somatostatin analogs 1999 ·Journal of Peptide Research ·(unknown), (unknown), (unknown), Chhavi Sharma, William A. Murphy, (unknown), (unknown), Gregory D. Espenan, Jay A. Nelson, Darrell R. Fisher, (unknown), M. Sue O’Dorisio, (unknown), Thomas M. O’Dorisio	13
12	Intraoperative Gamma Detection Of125I-Lanreotide in Women With Primary Breast Cancer 1999 ·Annals of Surgical Oncology ·(unknown), Edward A. Levine, Thomas M. O’Dorisio, James C. Watson, (unknown), Gregory D. Espenan, (unknown), (unknown), (unknown), Robertino M. Mera, M. Sue O’Dorisio, Eugene A. Woltering	13
13	DOSE-ESCALATION OF INDIUM-111 PENTETREOTIDE (SOMATOTHER™): TOXICITY AND CLINICAL RESPONSE. 1999 ·Clinical Nuclear Medicine ·(unknown), Lisa Lemen, Gregory D. Espenan, Eugene A. Woltering, J. Stuart Nelson, M. Cronin, Thomas J. Maloney, Lowell Anthony	2
14	EXPERIENCES WITH HIGH DOSE RADIOPEPTIDE THERAPY 1999 ·Health Physics ·Gregory D. Espenan, (unknown), Darrell R. Fisher, (unknown), Kevin E. McCarthy, Lowell Anthony, Thomas J. Maloney, Eugene A. Woltering	9
15	PREDICTIVE POWER AND LIMITATIONS OF THE DIAGNOSTIC SCAN FOR INDIUM-111 PENTETREOTIDE THERAPY 1999 ·Clinical Nuclear Medicine ·Lisa Lemen, Jean G. Nelson, Gregory D. Espenan, (unknown), Lowell Anthony, Eugene A. Woltering	1
16	Multiply Radioiodinated Somatostatin Analogs Induce Receptor-Specific Cytotoxicity 1998 ·Journal of Surgical Research ·Michael C. Meyers, Catherine T. Anthony, D.H. Coy, William A. Murphy, (unknown), Joseph A. Fuselier, Gregory D. Espenan, Thomas J. Maloney, Eugene A. Woltering	11

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact